TY - JOUR
T1 - Posterior reversible encephalopathy syndrome in childhood cancer
AU - de Laat, P.
AU - te Winkel, M. L.
AU - Devos, A. S.
AU - Catsman-Berrevoets, C. E.
AU - Pieters, R.
AU - van den Heuvel-Eibrink, M. M.
PY - 2011/2
Y1 - 2011/2
N2 - Background: Posterior reversible encephalopathy syndrome (PRES) is characterized by seizures, headaches, altered mental status, cortical blindness and typical transient lesions on magnetic resonance imaging. Patients and methods: We describe seven childhood cancer patients with clinical and radiological symptoms of PRES, and reviewed all well-documented PRES cases reported during childhood cancer treatment. Results: Fifty-six children with PRES, including our 7 cases, were identified in the literature. Mean age at onset was 9 (range: 2-17) years. Primary diagnoses were acute lymphoblastic leukemia (n = 31), acute myeloid leukemia (n = 5), non-Hodgkin lymphoma (n = 7) and solid tumors (n = 13). PRES patients presented with seizures (n = 50), altered mental status (n = 20), visual disturbances (n = 24) and/or headaches (n = 17). PRES was associated with hypertension in 49 patients. About 86% of the patients had both clinical and radiological reversible symptoms. Four patients developed epilepsy, in one patient ataxia remained and one patient had a persistent mydriasis. Conclusion: Although PRES has predominantly been described in leukemia patients, it occurs in children with solid tumors as well. Hypertension seems to be the most important trigger for the occurrence of PRES during childhood cancer treatment. Seizures are the most common accompanying sign. Symptoms and radiological findings normalize in ~90% of the cases, but in 10% neurological symptoms remain.
AB - Background: Posterior reversible encephalopathy syndrome (PRES) is characterized by seizures, headaches, altered mental status, cortical blindness and typical transient lesions on magnetic resonance imaging. Patients and methods: We describe seven childhood cancer patients with clinical and radiological symptoms of PRES, and reviewed all well-documented PRES cases reported during childhood cancer treatment. Results: Fifty-six children with PRES, including our 7 cases, were identified in the literature. Mean age at onset was 9 (range: 2-17) years. Primary diagnoses were acute lymphoblastic leukemia (n = 31), acute myeloid leukemia (n = 5), non-Hodgkin lymphoma (n = 7) and solid tumors (n = 13). PRES patients presented with seizures (n = 50), altered mental status (n = 20), visual disturbances (n = 24) and/or headaches (n = 17). PRES was associated with hypertension in 49 patients. About 86% of the patients had both clinical and radiological reversible symptoms. Four patients developed epilepsy, in one patient ataxia remained and one patient had a persistent mydriasis. Conclusion: Although PRES has predominantly been described in leukemia patients, it occurs in children with solid tumors as well. Hypertension seems to be the most important trigger for the occurrence of PRES during childhood cancer treatment. Seizures are the most common accompanying sign. Symptoms and radiological findings normalize in ~90% of the cases, but in 10% neurological symptoms remain.
KW - Childhood cancer
KW - Hypertension
KW - MRI
KW - Neurotoxicity
KW - Posterior reversible encephalopathy syndrome
KW - Seizures
UR - http://www.scopus.com/inward/record.url?scp=79251564434&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdq382
DO - 10.1093/annonc/mdq382
M3 - Article
C2 - 20699277
AN - SCOPUS:79251564434
SN - 0923-7534
VL - 22
SP - 472
EP - 478
JO - Annals of Oncology
JF - Annals of Oncology
IS - 2
ER -